Ptc Therapeutics (PTCT) Net Income towards Common Stockholders Growth (5y) (2017 - 2026)
Powered by 
Analysis
Ptc Therapeutics (PTCT) Net Income towards Common Stockholders Growth (5y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.81 Bn | 3.58 Bn | 340.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.02% |
| Mar 31, 2026 | 53.46% |
| Dec 31, 2025 | 33.92% |
| Sep 30, 2025 | 17.38% |
| Jun 30, 2025 | 18.60% |
| Mar 31, 2025 | 57.49% |
| Dec 31, 2024 | 3.24% |
| Sep 30, 2024 | -12.19% |
| Jun 30, 2024 | -18.87% |
| Mar 31, 2024 | -4.89% |
| Dec 31, 2023 | -26.01% |
| Sep 30, 2023 | -21.14% |
| Jun 30, 2023 | -83.65% |
| Mar 31, 2023 | -48.47% |
| Dec 31, 2022 | -167.34% |
| Sep 30, 2022 | -26.51% |
| Jun 30, 2022 | -54.15% |
| Mar 31, 2022 | -34.25% |
| Dec 31, 2021 | -39.83% |
| Sep 30, 2021 | -30.60% |